Future research efforts must be directed toward comprehensive molecular testing of lung cancer, allowing for the development of multimodal treatment strategies including immune checkpoint inhibitors, tyrosine kinase inhibitors, KRAS upstream inhibitors, and multi-kinase inhibitors against co-mutations. Here, KRAS is linked to lung cancer.